Xencor, Inc. (NASDAQ:XNCR) Director Sells $359,526.03 in Stock

Xencor, Inc. (NASDAQ:XNCR) Director Alan Bruce Montgomery sold 13,301 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $27.03, for a total transaction of $359,526.03. Following the completion of the sale, the director now directly owns 9,140 shares in the company, valued at approximately $247,054.20. The trade was a 59.27 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Alan Bruce Montgomery also recently made the following trade(s):

• On Wednesday, December 4th, Alan Bruce Montgomery sold 1,421 shares of Xencor stock. The stock was sold at an average price of $27.03, for a total value of $38,409.63.

Xencor Stock Performance

Shares of Xencor stock opened at $25.32 on Friday. The firm has a fifty day moving average of $22.41 and a two-hundred day moving average of $20.63. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a 52 week low of $15.31 and a 52 week high of $27.24.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $10.70 million during the quarter, compared to the consensus estimate of $14.59 million. During the same quarter in the prior year, the company posted ($0.40) earnings per share. The firm’s revenue was down 81.9% on a year-over-year basis. As a group, equities research analysts forecast that Xencor, Inc. will post -3.71 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on XNCR shares. BMO Capital Markets reissued an “outperform” rating and set a $34.00 price target (up from $32.00) on shares of Xencor in a report on Friday, November 8th. Piper Sandler raised Xencor from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $20.00 to $30.00 in a report on Monday. Royal Bank of Canada increased their price objective on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, September 26th. Wedbush reaffirmed an “outperform” rating and issued a $38.00 target price on shares of Xencor in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. raised their price target on shares of Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Xencor currently has an average rating of “Buy” and an average price target of $36.50.

Institutional Trading of Xencor

Hedge funds have recently modified their holdings of the company. Quarry LP acquired a new position in Xencor during the second quarter valued at approximately $36,000. KBC Group NV boosted its position in shares of Xencor by 63.5% during the third quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 1,213 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Xencor in the 2nd quarter valued at $154,000. XTX Topco Ltd bought a new stake in shares of Xencor in the 2nd quarter valued at $196,000. Finally, Rockefeller Capital Management L.P. bought a new stake in shares of Xencor in the 3rd quarter valued at $205,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.